Interestingly, Nguyen et al. [52] recently showed that the use of HDAC inhibitors such as Panobinostat, Vorinostat, and Romidepsin downregulated c-Myc expression and glycolytic enzymes, but upregulated OXPHOS in a GBM model. Here, MYC is linked to glioblastoma.